At a glance
| Field | Details |
|---|---|
| Brand names | Not yet approved |
| Targets | AMYR (amylin receptor — no GLP-1R involvement) |
| Developer | Zealand Pharma / Roche |
| Modality | SC injection, once-weekly |
| Approval status | Phase 2 — [verify Phase 3 initiation status] |
| Key efficacy | ~10.7% weight loss (Phase 2) |
| Indications | Obesity (standalone and combination) |
User Sentiment
Petrelintide's patient community is small but specific — people who've tried GLP-1 drugs and stopped due to intolerable side effects, and their advocates. For that group, the reaction to a weight loss drug that doesn't touch GLP-1R at all is qualitatively different from how the broader community receives new GLP-1 entrants.
Example(What the community says)
In GLP-1 forums, "I can't tolerate semaglutide or tirzepatide due to nausea" is a recurring post that typically ends in frustration — there's nothing else available. When petrelintide data comes up in these threads, the response is disproportionately engaged for a Phase 2 drug most people haven't heard of, because it represents an answer to a question the class hasn't had an answer for.
How it works
Not a GLP-1 drug. Petrelintide is a synthetic amylin analog that activates the amylin receptor (AMYR) without touching GLP-1R. This makes it mechanistically independent from every other drug in this series.
Amylin is a pancreatic hormone co-secreted with insulin after meals. It signals satiety through the area postrema and nucleus tractus solitarius in the brainstem — distinct from GLP-1's hypothalamic pathway. Amylin analogs slow gastric emptying, suppress glucagon, and reduce food intake, but through signaling architecture that doesn't depend on GLP-1R activation.
Why this matters: GLP-1 drugs cause nausea and vomiting as a direct consequence of GLP-1R activation in the gut. A subset of patients discontinues therapy despite benefit because the GI side effects are intolerable. Petrelintide offers pharmacological weight management through a different circuit — for patients who can't use the rest of this drug class, it may be the only option.
It also positions as a combination partner: petrelintide added to a GLP-1 agonist hits two satiety pathways simultaneously, similar to CagriSema's approach but as separately prescribable drugs rather than a fixed-dose combination.
Important(The patient population this drug serves)
GLP-1 drugs cause nausea and vomiting through direct GLP-1R activation in the gut. This is not a dosing problem or a titration problem — it's a mechanistic consequence of activating GLP-1R at all. A subset of patients discontinues despite clinical benefit because GI side effects are intolerable at any dose. For those patients, every drug in the rest of this series is unavailable. Petrelintide is the only pharmacological weight loss option that doesn't touch GLP-1R at all — and for that patient population, 10.7% from a well-tolerated weekly injection is not a consolation prize. It's the only option.
Trial data
Phase 2 [verify trial name]: ~10.7% weight loss — lower than GLP-1 agonists and dual agonists. The relevant comparison isn't semaglutide, it's the current alternative for GLP-1-intolerant patients: nothing pharmacological. 10.7% from a well-tolerated weekly injection is meaningful for that population.
Combination trial data with GLP-1 agonist background therapy [verify — Zealand has indicated combination studies are planned or ongoing].
What to Expect
Based on Phase 2 data and amylin receptor mechanism:
Weeks 1–4 — GI side effects through the amylin pathway are distinct from GLP-1-mediated nausea. Milder in Phase 2 than GLP-1 comparators for most participants.
Month 2–3 — Appetite reduction and gastric slowing via amylin pathway. Slower weight loss curve than GLP-1 drugs — 10.7% is the Phase 2 number, not the starting-point number.
As a combination — For patients who can tolerate both, petrelintide + a GLP-1 drug hits two satiety circuits simultaneously (similar to CagriSema but as separate drugs).
Not yet available — Phase 2 complete, Phase 3 timeline pending.
Dosing and administration
Once-weekly subcutaneous injection. Specific dose range and titration schedule [verify — Phase 2 protocol details not fully public].
Development status
| Milestone | Status |
|---|---|
| Phase 2 (standalone) | Complete — ~10.7% weight loss |
| Phase 2 (combination with GLP-1) | [verify status] |
| Phase 3 initiation | [verify — expected 2025–2026] |
| Roche partnership scope | [verify — commercialization rights details] |
| FDA filing | Timeline not yet public |
Safety profile
Amylin receptor agonism causes GI side effects through a distinct mechanism from GLP-1R activation. Phase 2 GI profile appeared milder than GLP-1 class comparators [verify discontinuation rates], which is the core tolerability proposition for GLP-1-intolerant patients. No GLP-1-related cardiovascular or thyroid signals applicable. Novel safety signals specific to petrelintide in Phase 2 [verify safety summary].
Who It's For
- People who've stopped a GLP-1 drug due to intolerable GI side effects
- BMI ≥ 30 or ≥ 27 with weight-related conditions
- Anyone whose provider has said GLP-1 drugs "aren't for you" due to tolerability — this mechanism is different
- AMYR agonism works independently, so it can be combined with GLP-1 drugs for patients who tolerate both
If you've been told you can't take GLP-1 drugs, petrelintide is worth asking your provider about specifically. It's a different pathway entirely.
Summary(The petrelintide picture)
~10.7% weight loss from a mechanism with no GLP-1R involvement. Not competing with semaglutide — serving the patient population that can't tolerate semaglutide. The combination with GLP-1 background therapy is the growth path: two satiety circuits for patients who can tolerate both, similar to CagriSema but as separate prescribable components.